Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023/24 season.
Núñez O, Olmedo C, Moreno-Perez D, Lorusso N, Fernández Martínez S, Pastor Villalba PE, Gutierrez Á, Alonso Garcia M, Latasa P, Sancho R, Mendioroz J, Martinez-Marcos M, Muñoz Platón E, García Rivera MV, Pérez-Martinez O, Álvarez-Gil R, Rivas Wagner E, López Gonzalez-Coviella N, Zornoza M, Barranco MI, Pacheco MDC, Álvarez Río V, Fiol Jaume M, Morey Arance R, Adiego Sancho B, Mendez Diaz M, Batalla N, Andreu C, Castilla J, García Cenoz M, Fernández Ibáñez A, Huerta Huerta M, Ibáñez Pérez AC, Berradre Sáenz B, Lamas J, Hermoso L, Casado Cobo S, Galán Cuesta M, Montenegro S, Domínguez M, Jarrín I, Limia A, Pastor-Barriuso R, Monge S; Nirsevimab Effectiveness Study Collaborators.
Núñez O, et al. Among authors: jarrin i.
Euro Surveill. 2025 Feb;30(5):2400596. doi: 10.2807/1560-7917.ES.2025.30.5.2400596.
Euro Surveill. 2025.
PMID: 39916606
Free PMC article.